Award
National Cancer Institute 11300256
Immune Checkpoint Blockade Targeting the Novel PSGL-1/VISTA Axis for Pancreatic Cancer
Recipient
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Award Amount
$209,674.00
Ceiling
$209,674.00
Awarded
February 26, 2026
Identifier
11300256
NIH grant awarded by the National Cancer Institute for research on pancreatic cancer immunotherapy targeting the PSGL-1/VISTA axis, with a project duration from March 2025 to February 2027 and an award amount of $209,674.
Description
This is a NIH grant opportunity for research on pancreatic cancer immunotherapy targeting PSGL-1/VISTA axis. The project involves developing a novel immunotherapy, evaluating biomarkers, and understanding immune responses. The project aims to address resistance to immune checkpoint blockade in pancreatic ductal adenocarcinoma (PDAC).